The relationship between prostate-specific antigen and prostate cancer risk: The prostate biopsy collaborative group

Clinical Cancer Research

Volumn 16, Issue 17, 2010, Pages 4374-4381

  Vickers, Andrew J ^a   Cronin, Angel M ^a   Roobol, Monique J ^b   Hugosson, Jonas ^c   Jones, J Stephen ^d   Kattan, Michael W ^d   Klein, Eric ^d   Hamdy, Freddie ^e   Neal, David ^f   Donovan, Jenny ^g   Parekh, Dipen J ^h   Ankerst, Donna ⁱ   Bartsch, George ^j   Klocker, Helmut ^j   Horninger, Wolfgang ^j   Benchikh, Amine ^k   Salama, Gilles ^l   Villers, Arnauld ^m   Freedland, Steve J ⁿ   Moreira, Daniel M ⁿ   Schröder, Fritz H ^b   Lilja, Hans ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g UNIVERSITY OF BRISTOL   (United Kingdom)

^h UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

ⁱ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^j INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^k BICHAT HOSPITAL   (France)

^l Centre Hospitalier Intercommunal Castres Mazamet   (France)

^m LILLE UNIVERSITY HOSPITAL   (France)

ⁿ DUKE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RISK; COHORT ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY; PROSTATE BIOPSY; PROSTATE CANCER; RISK ASSESSMENT;

AGED; BIOPSY; EUROPE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 77956255132     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1328     Document Type: Article

References (19)

1. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004; 172:1297-301.
2. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005;294:66-70. (Pubitemid 41002840)
3. Schroder FH, Bangma CH, Roobol MJ. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC. Eur Urol 2008;53:901-8.
4. Schroder F, Kattan MW. The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review. Eur Urol 2008;54:274-90.
5. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
6. Parekh DJ, Ankerst DP, Higgins BA, et al. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology 2006;68:1152-5.
7. Bartsch G, Horninger W, Klocker H, et al. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int 2008;101:809-16.
8. Donovan J, Mills N, Smith M, et al. Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult. BMJ 2002;325:766-70.
9. Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc 1979;74:829-36.
10. Lawrentschuk N, Toi A, Lockwood GA, et al. Operator is an independent predictor of detecting prostate cancer at transrectal ultrasound guided prostate biopsy. J Urol 2009;182:2659-63.
11. Eastham JA, Riedel E, Scardino PT, et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 2003;289:2695-700.
12. Lilja H, Ulmert D, Bjork T, et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol 2007;25:431-6.
13. Ulmert D, Cronin AM, Bjork T, et al. Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med 2008;6:6.
14. Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific antigen and its complex with α 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994;344:1594-8.
15. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006;98:529-34.
16. Kranse R, Roobol M, Schroder FH. A graphical device to represent the outcomes of a logistic regression analysis. Prostate 2008;68: 1674-80.
17. van den Bergh RC, Roobol MJ, Wolters T, Van Leeuwen PJ, Schröder FH. The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison. BJU Int 2008; 102:1068-73.
18. Vickers AJ, Cronin AM, Roobol MJ, et al. Reducing unnecessary biopsy during prostate cancer screening using a four kallikrein panel: an independent replication. J Clin Oncol 2010;28:2493-8.
19. Schwartz MJ, Hwang DH, Hung AJ, et al. Negative influence of changing biopsy practice patterns on the predictive value of prostate- specific antigen for cancer detection on prostate biopsy. Cancer 2008;112:1718-25.